The Challenge
Malaria is a serious and life-threatening, mosquito borne disease prevalent across much of tropical and sub-tropical Asia, South America and Sub-Saharan Africa. Due to increasing resistance to current antimalarial regimens, new drugs are required as both stand-alone and partner therapies to address a growing medical need. New therapies will not only reduce mortality and disease in vulnerable populations, but also to help the move towards a greater goal of malaria elimination. Malaria is classified as an unmet need in healthcare. In 2015 the World Health Assembly endorsed aims to reduce malaria burden by 90% by 2030.
Here at hVIVO, we are developing further capability and capacity in its unique Human Challenge facilities to assist in the advancement of novel antimalarial drug and vaccine candidates and is now able to offer a Direct Venous Inoculation (DVI), Controlled Human Malaria Infection (CHMI) model for estimations of efficacy. Results from CHMI modelling of drug and vaccine efficacy have shown good translation into the field.
hVIVO plc (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services for its broad and long-standing client base of biopharma companies.
